Chronic pancreatitis (CP) is a progressive disease, often leading to loss of exocrine and endocrine function and debilitating abdominal pain. It is unknown why some individuals progress and develop complications, including pancreatogenic diabetes (PDM) and/or pancreas cancer (PDAC). In this consortium, investigators propose to conduct well-powered studies of risk factors, environmental influences, and proof-of-concept studies to move the field forward, particularly those factors that increase the risk of PDM and PDAC. We propose the following specific aims (SA) to meet the goals of RFA-DK-14-027. SA #1: To define the natural history of pediatric and adult patients with an established diagnosis of CP or acute recurrent pancreatitis, we propose a prospective observational cohort study. We will place emphasis on identifying risk factors and phenotypes for those patients who develop PDM and/or PDAC. Biological specimens will be obtained to facilitate the study of possible biomarkers which might facilitate early disease diagnosis and management. SA #2: The pathogenesis of PDM and the interactions of non-endocrine pancreatic disease with islet dysfunction are not well understood. We will use measurements of islet function (oral glucose tolerance tests, arginine- augmented hyperglycemic clamps) in cross-sectional and prospective studies to define the prevalence and physiologic basis for metabolic dysregulation and diabetes in CP. We will also prospectively ascertain changes in islet function and transition to overt PDM, and correlate changes in metabolic status with changes in pancreatic inflammation and function. SA #3: To evaluate the diagnostic efficacy of Magnetic Resonance (MR) imaging in the non-invasive evaluation of suspected early CP, we propose a prospective study comparing CP patients to a control population with normal pancreatic exocrine function. A reduced T1-weighted MR signal, reduced diffusion and decreased duodenal fluid volume in response to secretin stimulation may suggest CP. SA #4: Galectin-3 (Gal-3) is a carbohydrate-binding protein which appears to be involved in fibrogenesis and tissue remodeling in CP. A Gal-3 inhibitor appears to be safe and shows potential for reducing organ fibrosis in humans. To determine the safety and efficacy of a Gal-3 inhibitor, we propose a randomized placebo- controlled trial in 66 CP patients. Improvement in post-therapy duodenal fluid bicarbonate level will be the primary efficacy endpoint. We anticipate that this drug will reverse fibrosis, as manifested by improvement in duodenal bicarbonate level. Additional endpoints including MRI/MRCP appearance, Gal-3 level, quality of life, abdominal pain scores and ?-cell function will also be assessed.

Public Health Relevance

Chronic pancreatitis (CP) is a progressive, unrelenting disease, often leading to loss of exocrine and endocrine function and debilitating abdominal pain, resulting in significant healthcare costs. It is unknown why some individuals progress to severe disease and develop serious complications, including diabetes and/or pancreas cancer. In this consortium, investigators from several institutions propose to conduct well-powered studies of risk factors, environmental influences, and proof-of-concept studies to move the field forward, particularly those factors that increase the risk of diabetes and malignancy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01DK108323-01
Application #
9045156
Study Section
Special Emphasis Panel (ZDK1-GRB-8 (O1))
Program Officer
Serrano, Jose
Project Start
2015-09-28
Project End
2020-08-31
Budget Start
2015-09-28
Budget End
2016-08-31
Support Year
1
Fiscal Year
2015
Total Cost
$287,655
Indirect Cost
$103,261
Name
Indiana University-Purdue University at Indianapolis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Tirkes, Temel; Lin, Chen; Cui, Enming et al. (2018) Quantitative MR Evaluation of Chronic Pancreatitis: Extracellular Volume Fraction and MR Relaxometry. AJR Am J Roentgenol 210:533-542
Eibl, Guido; Cruz-Monserrate, Zobeida; Korc, Murray et al. (2018) Diabetes Mellitus and Obesity as Risk Factors for Pancreatic Cancer. J Acad Nutr Diet 118:555-567
Serrano, Jose; Andersen, Dana K; Forsmark, Christopher E et al. (2018) Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer: From Concept to Reality. Pancreas 47:1208-1212
Tirkes, Temel (2018) Chronic Pancreatitis: What the Clinician Wants to Know from MR Imaging. Magn Reson Imaging Clin N Am 26:451-461
Fisher, William E; Cruz-Monserrate, Zobeida; McElhany, Amy L et al. (2018) Standard Operating Procedures for Biospecimen Collection, Processing, and Storage: From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Pancreas 47:1213-1221
Uc, Aliye; Perito, Emily R; Pohl, John F et al. (2018) INternational Study Group of Pediatric Pancreatitis: In Search for a CuRE Cohort Study: Design and Rationale for INSPPIRE 2 From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Pancreas 47:1222-1228
Hart, Phil A; Andersen, Dana K; Mather, Kieren J et al. (2018) Evaluation of a Mixed Meal Test for Diagnosis and Characterization of PancrEaTogEniC DiabeTes Secondary to Pancreatic Cancer and Chronic Pancreatitis: Rationale and Methodology for the DETECT Study From the Consortium for the Study of Chronic Pancreatitis Pancreas 47:1239-1243
Tirkes, Temel; Fogel, Evan L; Sherman, Stuart et al. (2017) Detection of exocrine dysfunction by MRI in patients with early chronic pancreatitis. Abdom Radiol (NY) 42:544-551
Fogel, Evan L; Shahda, Safi; Sandrasegaran, Kumar et al. (2017) A Multidisciplinary Approach to Pancreas Cancer in 2016: A Review. Am J Gastroenterol 112:537-554
Ridtitid, Wiriyaporn; Lehman, Glen A; Watkins, James L et al. (2017) Short- and long-term outcomes from percutaneous endoscopic gastrostomy with jejunal extension. Surg Endosc 31:2901-2909

Showing the most recent 10 out of 24 publications